Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18F-FDG PET/CT and MRI

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1553-1562

  Byun, Byung Hyun ^a   Kong, Chang Bae ^a,b   Lim, Ilhan ^a   Kim, Byung Il ^a   Choi, Chang Woon ^a   Song, Won Seok ^a   Cho, Wan Hyeong ^a   Jeon, Dae Geun ^a   Koh, Jae Soo ^b   Lee, Soo Yong ^a   Lim, Sang Moo ^a,b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

chemotherapy; MRI; osteosarcoma; PET CT

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG UPTAKE; GLYCOLYSIS; HUMAN; METABOLIC TUMOR VOLUME; MONITORING; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOSARCOMA; PET-CT SCANNER; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TOTAL LESION GLYCOLYSIS; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ADOLESCENT; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; FEMALE; MALE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905561105     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2746-2     Document Type: Article

References (34)

1. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836-45. (Pubitemid 41713121)
2. Hagleitner MM, de Bont ES, Te Loo DM. Survival trends and longterm toxicity in pediatric patients with osteosarcoma. Sarcoma. 2012;2012:636405.
3. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-27. (Pubitemid 32038393)
4. Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20:955-60.
5. Bajpai J, Gamnagatti S, Kumar R, Sreenivas V, Sharma MC, Khan SA, et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol. 2011;41:441-50.
6. Jeon DG, Song WS. How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther. 2010;10:1313-25.
7. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol. 2005;123:75-90. (Pubitemid 40066173)
8. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-31. (Pubitemid 24056419)
9. Wellings RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ. The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol. 1994;49:19-23. (Pubitemid 24014563)
10. Ongolo-Zogo P, Thiesse P, Sau J, Desuzinges C, Blay JY, Bonmartin A, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadoliniumenhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol. 1999;9:907-14.
11. Holscher HC, Bloem JL, Nooy MA, Taminiau AH, Eulderink F, Hermans J. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR Am J Roentgenol. 1990;154:763-9. (Pubitemid 20114593)
12. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340-7.
13. Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH, Song WS, et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med. 2009;50:1435-40.
14. Kong CB, Byun BH, Lim I, Choi CW, Lim SM, Song WS, et al. (18)F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging. 2013;40:728-36.
15. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-55.
16. Delso G, Ziegler S. PET/MRI system design. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S86-92.
17. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928-38.
18. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244-52.
19. Holscher HC, Bloem JL, van der Woude HJ, Hermans J, Nooy MA, Taminiau AH, et al. Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? Clin Radiol. 1995;50:384-90.
20. Holscher HC, Bloem JL, Vanel D, Hermans J, Nooy MA, Taminiau AH, et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology. 1992;182:839-44.
21. Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.
22. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55-67. (Pubitemid 13040824)
23. Byun BH, Kong CB, Park J, Seo Y, Lim I, Choi CW, et al. Initial Metabolic Tumor Volume Measured by 18F-FDG PET/CT Can Predict the Outcome of Osteosarcoma of the Extremities. J Nucl Med. 2013;54:1725-32.
24. Kim MS, Lee SY, Cho WH, SongWS, Koh JS, Lee JA, et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol. 2008;15:906-14.
25. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848-58. (Pubitemid 26085530)
26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Ill AT. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010. p. 143-64.
27. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res. 2002;397:53-61. (Pubitemid 34442015)
28. Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis. J Pediatr Hematol Oncol. 2008;30:419-24.
29. Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med. 2013;54:1053-9.
30. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skelet Radiol. 1998;27:57-71. (Pubitemid 28181732)
31. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559-66.
32. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med. 2003;44:930-42. (Pubitemid 40003746)
33. Werner MK, Schmidt H, Schwenzer NF. MR/PET: a new challenge in hybrid imaging. AJR Am J Roentgenol. 2012;199:272-7.
34. Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel BA. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med. 2009;50:1187-93.